Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Abstract Background Pragmatic use of the anti-fibrotic medications pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF) in the United States (US) has not been studied and may be different from international settings due to structural differences between health care systems. This study...

Full description

Bibliographic Details
Main Authors: Colin H. Holtze, Elizabeth A. Freiheit, Susan L. Limb, John L. Stauffer, Karina Raimundo, Wayne T. Pan, Kevin R. Flaherty, Hyun J. Kim
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Respiratory Research
Subjects:
Idiopathic pulmonary fibrosis
Therapeutics
Clinical decision-making
Online Access:https://doi.org/10.1186/s12931-020-1315-4

Internet

https://doi.org/10.1186/s12931-020-1315-4

Similar Items